| Identification | Back Directory | [Name]
1-Hydroxy-6-phenyl-4-trifluoroMethyl-1H-indole-2-carboxylic acid | [CAS]
1269802-68-7 | [Synonyms]
LDHA-IN-1
KGXDBNBXAPVUIM-UHFFFAOYSA-N
1-Hydroxy-6-phenyl-4-trifluoroMethyl-1H-indole-2-carboxylic acid
1-hydroxy-4-(trifluoromethyl)-6-phenyl-1H-indole-2-carboxylic acid
1H-Indole-2-carboxylic acid, 1-hydroxy-6-phenyl-4-(trifluoromethyl)- | [Molecular Formula]
C16H10F3NO3 | [MDL Number]
MFCD20257232 | [MOL File]
1269802-68-7.mol | [Molecular Weight]
321.25 |
| Chemical Properties | Back Directory | [Boiling point ]
556.2±60.0 °C(Predicted) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 100mg/mL | [form ]
solid | [pka]
2.88±0.30(Predicted) | [color ]
off-white |
| Hazard Information | Back Directory | [Uses]
A cell-permeable, non-cytotoxic N-hydroxyindole (NHI) carboxylate that acts as a potent, reversible, and isoform selective inhibitor of lactic dehydrogenase (LDH) A/LDH-1. Inhibition appears to be competitive with respect to both pyruvate (Ki = 4.7 μM) and NADH (cofactor; Ki = 8.9 μM). Acts by occupying the whole substrate pocket and part of the cofactor pocket of LDH-A. Blocks the growth of various cancer cell lines by causing an arrest at G1 phase and inducing apoptosis (IC50 = 10.8, 10.6, 11.4, and 31.5 μM for A2780/cOHP, MSTO-211H, NIH-H28, and H630 cells, respectively). Exhibits enhanced anticancer activity under hypoxic conditions (GI50 = 0.90 μM/hypoxia vs. 16.3 μM/normoxia in LPC006 cultures) and strongly synergizes with gemcitabine.Please note that the molecular weight for this compound is batch-specific due to variable water content. Please refer to the vial label or the certificate of analysis for the batch-specific molecular weight. The molecular weight provided represents the baseline molecular weight without water. | [Biological Activity]
Cell permeable: yes''Primary Target
LDH-A/LDH-1''Target IC50: 10.810.611.4and 31.5 µ |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|